Biotechnology Risk Management Law In Russia.
1. Introduction
Biotechnology Risk Management Law in Russia refers to the legal framework governing the identification, assessment, prevention, control and mitigation of risks arising from biotechnology research, genetic engineering, genetically modified organisms (GMOs), biological materials, pharmaceutical biotechnology, genetic testing, clinical trials and industrial biological production.
Russia does not regulate all biotechnology risks through one comprehensive statute. Instead, it follows a multi-layered regulatory framework involving constitutional protections, civil liability, public-health legislation, sanitary and epidemiological controls, environmental protection, genetic-engineering regulation, pharmaceutical legislation and biological safety measures.
The principal objective is to protect:
Human life and public health.
The environment and biological diversity.
Researchers, laboratory employees and healthcare professionals.
Consumers of biotechnology-derived products.
Agricultural and animal populations.
National biological security and public safety.
An important distinction is that biotechnology risk management is broader than GMO regulation. It also covers laboratory accidents, contamination, clinical-trial failures, unsafe medicines, biological-agent exposure, genetic-data misuse and environmental damage.
2. Constitutional foundations
The Russian Constitution provides the foundation for biotechnology risk management.
| Article | Constitutional protection | Relevance |
|---|---|---|
| Article 20 | Right to life | Protection against serious biological hazards |
| Article 21 | Human dignity | Protection against coercive or unsafe experimentation |
| Article 41 | Right to health protection and medical assistance | Safe medical and biotechnology practices |
| Article 42 | Right to a favourable environment | Prevention of environmental biotechnology damage |
| Article 45 | State protection of rights and freedoms | Access to legal remedies |
| Article 58 | Duty to preserve nature and the environment | Environmental responsibility |
| Article 71 | Federal powers | Federal regulation of matters including defence and security |
| Article 72 | Shared federal and regional competence | Environmental and public-health regulation |
These constitutional provisions support preventive regulation, government supervision and legal remedies where biotechnology activities threaten human health or the environment.
3. Principal legislation governing biotechnology risk management
A. Federal Law No. 492-FZ of 30 December 2020 – On Biological Safety
Principal biological safety legislation
Federal Law No. 492-FZ is one of the most important laws governing biological risk management in Russia.
Its purpose is to establish a system for protecting the population and the environment from dangerous biological factors and preventing biological threats.
The law recognises biological risk as the probability of harm to human health, animals, plants or the environment resulting from dangerous biological factors.
Important provisions:
Article 1: Defines biological safety, biological risks, dangerous biological factors and biological threats.
Article 3: Establishes principles of biological safety.
Article 5: Defines the powers of federal, regional and local authorities.
Articles 6–7: Establish rights and obligations of citizens and organisations.
Article 8: Identifies principal biological threats.
Article 9: Provides for protective measures and biological-risk monitoring.
Article 10: Addresses the prevention and control of infectious and parasitic diseases.
Article 11: Regulates collection-related activities involving pathogenic microorganisms and viruses.
Article 12: Addresses accidents, sabotage and other threats involving potentially dangerous biological facilities.
Article 13: Establishes biological-risk monitoring.
Article 14: Provides for a state information system on biological safety.
Article 16: Addresses liability for violations of biological-safety legislation.
Application to biotechnology:
A biotechnology research institution working with dangerous microorganisms must consider biological risks, appropriate protective arrangements, institutional responsibilities and applicable licensing requirements.
The law also provides a framework for monitoring biological threats and coordinating public authorities.
Consultant Plus+1
B. Federal Law No. 86-FZ of 5 July 1996 – On State Regulation in the Field of Genetic Engineering Activities
This is the principal statute governing genetic-engineering activities.
It regulates genetic engineering in relation to environmental protection, ecological safety and human health.
Its regulatory relevance includes:
Genetic-engineering research.
Genetically engineered modified organisms.
Registration of relevant organisms and products.
Safety requirements for genetic-engineering activities.
Genetic information and genetic data.
Government oversight and responsibility.
The amendments introduced by Federal Law No. 643-FZ of 29 December 2022 expanded the statute's treatment of genetic information and genetic data.
Risk-management significance: Genetic-engineering organisations cannot treat the creation or use of modified organisms as an entirely private scientific activity. Applicable statutory safety and registration requirements must be observed.
CIS Legislation+1
C. Federal Law No. 52-FZ of 30 March 1999 – On Sanitary and Epidemiological Well-Being of the Population
This law protects public health against harmful environmental, biological and epidemiological factors.
Its importance in biotechnology includes:
Sanitary requirements for laboratories.
Prevention of infectious disease transmission.
Health protection of laboratory employees.
Sanitary supervision of production facilities.
Prevention of contamination.
Compliance with applicable hygiene standards.
For example, a laboratory handling biological materials must comply with the applicable sanitary and epidemiological requirements. Failure to maintain appropriate safety conditions may result in administrative enforcement and, where the relevant elements are established, civil or criminal liability.
D. Federal Law No. 7-FZ of 10 January 2002 – On Environmental Protection
This legislation establishes general environmental-protection obligations.
It is relevant where biotechnology activities involve:
Environmental release of genetically engineered organisms.
Biological contamination of land and water.
Damage to ecosystems.
Unsafe disposal of biological waste.
Industrial biotechnology pollution.
Article 77 is particularly important because it provides the statutory basis for compensation for environmental damage caused by violations of environmental legislation.
Article 78 addresses the procedure for determining compensation for environmental damage.
The law must be read together with the Civil Code and environmental assessment legislation.
E. Federal Law No. 174-FZ of 23 November 1995 – On Environmental Expert Review
This law provides for environmental expert review of projects and activities falling within its statutory scope.
Its relevance to biotechnology is particularly important when a proposed project could affect ecological safety.
For example, a proposed biotechnology facility or activity involving environmental release may require the applicable environmental assessment or expert review.
A project should not assume that scientific approval alone eliminates its environmental-law obligations.
F. Federal Law No. 323-FZ of 21 November 2011 – On the Fundamentals of Health Protection of Citizens
This law regulates medical activities and the protection of patients.
Its biotechnology relevance includes:
Patient safety.
Informed consent.
Medical experimentation.
Clinical research.
Medical confidentiality.
Healthcare-provider responsibility.
Protection of vulnerable patients.
Biotechnology-derived medicines and advanced medical technologies must comply with the applicable medical and pharmaceutical regulatory requirements.
G. Federal Law No. 61-FZ of 12 April 2010 – On the Circulation of Medicines
This law regulates the development, testing, registration, manufacture and circulation of medicinal products.
It is particularly important for biotechnology-derived medicines, including certain biological medicines, recombinant proteins, vaccines and other biological pharmaceutical products.
The regulatory framework addresses quality, efficacy, safety, manufacturing standards and pharmacovigilance.
A biotechnology medicine cannot lawfully enter the relevant regulated market merely because its developer considers it scientifically promising.
H. Government Resolution No. 35 of 18 January 2023
This resolution establishes the procedure for state registration of genetically engineered modified organisms intended for environmental release and products obtained using or containing such organisms.
It is important because it connects GMO risk assessment with registration and regulatory monitoring.
The relevant responsibilities include:
Registration according to intended use.
Monitoring by Rospotrebnadzor and Rosselkhoznadzor within their respective areas.
Maintenance of a consolidated state register by the Ministry of Health.
Control over environmental release.
CIS Legislation+1
4. Institutional framework and regulatory authorities
Russia uses several public authorities to manage biotechnology risks.
| Authority | Main responsibilities |
|---|---|
| Ministry of Health | Health policy and relevant biological-product registration functions |
| Rospotrebnadzor | Sanitary and epidemiological supervision |
| Roszdravnadzor | Supervision of healthcare and medicinal-product circulation |
| Rosselkhoznadzor | Veterinary and phytosanitary supervision |
| Rosprirodnadzor | Environmental supervision |
| Ministry of Natural Resources | Environmental policy and regulatory coordination |
| Federal Security Service | Relevant national-security functions |
| Regional authorities | Implementation of applicable regional and federal requirements |
The division of authority is important because a biotechnology project may simultaneously require medical, environmental, sanitary, agricultural and industrial compliance.
5. Risk assessment and prevention mechanisms
Russian biotechnology risk management can be understood through six principal stages.
5.1 Identification of biological risks
The first stage involves identifying possible sources of harm.
Examples include:
Pathogenic microorganisms.
Genetically modified organisms.
Recombinant biological materials.
Contaminated biological samples.
Unsafe laboratory procedures.
Biological pharmaceutical products.
Improperly stored biological specimens.
5.2 Risk classification
Risks should be evaluated according to their nature and potential consequences.
| Risk category | Example |
|---|---|
| Human-health risk | Exposure to pathogenic microorganisms |
| Environmental risk | Uncontrolled release of modified organisms |
| Laboratory risk | Accidental biological contamination |
| Pharmaceutical risk | Unsafe biological medicines |
| Agricultural risk | Spread of unregistered GM organisms |
| Data-related risk | Unauthorised disclosure of genetic information |
| National-security risk | Misuse of dangerous biological materials |
The applicable statutory classification and licensing requirements depend on the biological agent and the activity involved.
5.3 Risk assessment
Assessment should examine:
Probability of an adverse event.
Severity of potential harm.
Exposure pathways.
Duration of exposure.
Vulnerability of affected populations.
Possibility of environmental spread.
Available preventive measures.
Scientific evidence and appropriate laboratory testing are essential components of the assessment.
5.4 Risk prevention
Organisations should implement suitable preventive arrangements, including:
Appropriate laboratory containment.
Personnel training.
Access control.
Safe storage and transportation.
Biological-waste management.
Equipment maintenance.
Emergency response procedures.
Documentation and internal audits.
5.5 Monitoring and reporting
Risk management continues after research or product approval.
Monitoring may identify previously unknown adverse effects, unexpected biological behaviour or contamination.
The biological-risk monitoring framework under Federal Law No. 492-FZ is especially relevant here.
5.6 Remediation and liability
Where an accident occurs, the responsible organisation may face several forms of legal consequences:
Administrative penalties.
Civil compensation.
Environmental restoration obligations.
Suspension of relevant activities.
Withdrawal or recall of products.
Criminal prosecution where the statutory elements of an offence are established.
6. Important case laws and judicial decisions
Russian biotechnology risk-management jurisprudence is still developing. There are relatively few reported judgments dealing specifically with genetic engineering or GMO-related accidents. However, clinical-trial safety decisions, GMO enforcement proceedings and environmental judgments provide important legal principles.
The following cases should be distinguished according to whether they directly concern biotechnology or provide related legal guidance.
Case 1. Traskunova v. Russia (2022)
Important biotechnology-related judgment
European Court of Human Rights · Application No. 21648/11 · Judgment of 30 August 2022
Facts:
The applicant's daughter participated in clinical trials involving a new medicinal product intended to treat schizophrenia.
The participant died during the period of clinical-trial participation.
The applicant alleged that the Russian authorities had failed to provide adequate protection of the participant's right to life.
Legal issues:
Whether clinical-trial participants received sufficient protection.
Whether informed consent safeguards were properly implemented.
Whether the regulatory authorities fulfilled their positive obligations.
Whether the investigation into the death was adequate.
Judgment:
The European Court of Human Rights found a violation of Article 2 of the European Convention on Human Rights.
The Court emphasised that experimental medicinal products carry inherent risks because their safety and efficacy may not be fully established.
It also stressed that the State has positive obligations to adopt and implement safeguards protecting participants in clinical trials.
Importance for biotechnology risk management:
This judgment is particularly relevant to biotechnology-derived medicines, experimental treatments and advanced pharmaceutical research.
It establishes an important principle: regulatory approval does not remove the State's responsibility to ensure effective protection of clinical-trial participants.
It also highlights the importance of informed consent, ethical safeguards and effective investigation of serious adverse events.
Temidy
Case 2. Supreme Court of the Russian Federation – Unregistered Genetically Modified Rapeseed (2023)
Case No. 9-АД23-12-К1 · 19 September 2023
Facts:
Agricultural authorities identified the cultivation of genetically modified rapeseed containing the CP4 EPSPS genetic element on agricultural land in the Nizhny Novgorod region.
The relevant cultivation involved several agricultural plots.
The regulatory dispute concerned the use of genetically engineered material without the required state registration.
Legal issue:
Whether cultivation of unregistered genetically modified agricultural material could result in administrative liability.
Judicial outcome:
The reported decision upheld administrative liability against the agricultural company.
The penalty was RUB 250,000 under Article 6.3.1 of the Code of Administrative Offences.
Legal significance:
This proceeding illustrates the importance of GMO registration and regulatory supervision.
It demonstrates that agricultural biotechnology operators must comply with the applicable registration requirements rather than relying exclusively on the commercial or scientific usefulness of a genetically modified product.
Research qualification: The case details are reported in secondary legal commentary. The official judgment should be obtained and checked before relying on its precise factual findings or procedural history in formal legal proceedings.
Law Gratis
Case 3. Kotov and Others v. Russia (2022)
European Court of Human Rights · Application No. 6142/18 · 11 October 2022
Facts:
The case concerned environmental conditions associated with waste-processing activities and their potential consequences for people living in the affected area.
The applicants raised complaints concerning environmental hazards and the State's obligations to protect private and family life.
Legal significance:
The judgment examined the Russian legal framework concerning:
Article 42 of the Russian Constitution.
Civil Code Articles 1064 and 1065.
Environmental protection legislation.
Administrative and judicial remedies.
The State's positive obligations under Article 8 of the European Convention.
Application to biotechnology:
Although this was not a biotechnology dispute, its environmental-law principles are relevant when a biotechnology facility causes pollution, biological contamination or environmental hazards affecting neighbouring communities.
It supports the importance of effective environmental monitoring and judicial protection against serious environmental interference.
BAILII
Case 4. Russian Supreme Court Plenum Resolution No. 49 of 30 November 2017
Subject: Application of legislation concerning compensation for environmental damage.
This is an important judicial interpretative authority for environmental liability.
Its relevance includes:
Compensation for environmental damage.
Assessment of environmental harm.
Application of environmental liability principles.
Prevention of activities creating a real danger of environmental damage.
The relationship between regulatory compliance and judicial remedies.
Application to biotechnology:
Suppose a biotechnology company proposes releasing a genetically modified organism into an environmentally sensitive area.
If the proposed activity creates a real and legally demonstrable danger of environmental harm, preventive judicial remedies may be available under Article 1065 of the Civil Code.
The claimant must establish the relevant legal and factual requirements.
The important principle is that environmental protection is not limited to compensation after damage has already occurred. Preventive judicial protection may also be relevant.
Case 5. Hristozov and Others v. Bulgaria (2012)
European Court of Human Rights · Applications Nos. 47039/11 and 358/12 · 13 November 2012
Facts:
The applicants sought access to an experimental cancer treatment that had not received the necessary marketing authorisation.
They challenged the national regulatory restrictions governing access to experimental medicines.
Judgment:
The European Court examined the relationship between access to experimental medicines, the right to respect for private life and the State's regulatory discretion.
The Court did not find a violation of Article 8 in the circumstances of the case.
Importance for Russian biotechnology law:
Although this judgment concerned Bulgaria rather than Russia, it provides comparative guidance on the balance between:
Patient autonomy.
Experimental treatment access.
Pharmaceutical safety.
Regulatory authorisation.
Protection against unproven medical interventions.
It is useful for analysing the legal risks associated with experimental biotechnology therapies.
Temidy
7. Civil liability for biotechnology-related damage
The Russian Civil Code is an important instrument for determining liability when biotechnology activities cause injury or property damage.
Article 15 – Compensation for losses
A person whose rights have been violated may seek compensation for losses where the statutory requirements are satisfied.
For example, if a biotechnology production facility damages neighbouring agricultural property, the affected party may seek compensation.
Article 1064 – General tort liability
This provision establishes the general principle that damage caused to a person or property must be compensated by the person responsible, subject to the applicable statutory rules.
Examples include:
Injury caused by negligent laboratory operations.
Damage caused by biological contamination.
Harm resulting from unsafe biotechnology manufacturing.
Damage to third-party property.
Article 1065 – Prevention of harm
This provision is particularly significant for biotechnology risk management.
It permits a claim seeking prohibition of activities that create a danger of future harm.
For example, if a biotechnology facility presents a demonstrable danger of biological contamination, preventive judicial intervention may be sought.
Article 1079 – Liability for activities involving increased danger
This provision concerns liability arising from activities that create increased danger to others.
Its application to a particular biotechnology operation depends on whether the activity qualifies under the statutory test.
It should not automatically be assumed that every biotechnology laboratory or pharmaceutical facility falls within Article 1079.
Article 1085 – Compensation for injury to health
Where biotechnology-related activities cause personal injury, the provisions concerning compensation for harm to health may become relevant.
Potential claims can include legally recoverable medical expenses, loss of earnings and other recognised losses.
8. Administrative and criminal liability
A. Administrative liability
The Russian Code of Administrative Offences provides mechanisms for enforcement against organisations and individuals violating applicable biotechnology-related requirements.
Important provisions include:
| Provision | Legal subject |
|---|---|
| Article 6.3 | Violations of sanitary and epidemiological requirements |
| Article 6.3.1 | Violations involving requirements applicable to genetically engineered organisms |
| Article 8.1 | Failure to comply with environmental-protection requirements |
| Article 8.2 | Violations of waste-management requirements |
| Article 10.6 | Violations of rules concerning quarantine and plant protection, where applicable |
The precise offence, responsible person and applicable penalty depend on the facts and the version of the Code in force.
B. Criminal liability
The Russian Criminal Code may apply when biotechnology-related conduct satisfies the elements of a criminal offence.
Relevant provisions include:
Article 236: Violations of sanitary and epidemiological rules resulting in the consequences specified by the statute.
Article 247: Violations of rules governing environmentally hazardous substances and waste.
Article 248: Violations of safety rules governing microbiological or other biological agents and toxins.
Article 249: Violations of veterinary rules and regulations governing plant diseases and pests.
For instance, a serious laboratory safety breach involving dangerous biological agents could potentially attract Article 248 where its legal elements are established.
Criminal liability is not automatic merely because an accident occurs. The prosecution must establish the relevant offence, including the required fault, conduct and consequences.
9. International and comparative framework
Russian biotechnology risk management also operates within relevant international and regional frameworks.
| Instrument | Relevance |
|---|---|
| Convention on Biological Diversity, 1992 | Conservation of biological diversity |
| Cartagena Protocol on Biosafety, 2000 | Safe handling, transport and use of living modified organisms, subject to applicable treaty status |
| Biological Weapons Convention, 1972 | Prohibition of biological and toxin weapons |
| International Health Regulations, 2005 | Prevention and response to international public-health threats |
| Eurasian Economic Union regulations | Harmonisation of relevant pharmaceutical, food and product-safety requirements |
These instruments address different aspects of biological safety. Their application must be assessed according to Russia's treaty obligations, reservations, participation status and applicable domestic implementing legislation.
10. Major legal challenges
Russia's biotechnology risk-management framework faces several important legal challenges.
1. Scientific uncertainty
New genetic technologies may produce unexpected biological effects. Regulators must evaluate risks using reliable scientific evidence.
2. Regulatory fragmentation
Biotechnology activities may fall under several different regulatory authorities. Coordination is necessary to prevent gaps in supervision.
3. Environmental liability
Determining whether a genetically modified organism caused environmental damage may require complex scientific evidence and expert analysis.
4. Clinical-trial protection
Experimental biotechnology medicines create risks involving informed consent, vulnerable patients, adverse-event reporting and medical supervision.
5. Genetic-data protection
Genetic information creates privacy and confidentiality risks. Federal Law No. 86-FZ and the general personal-data framework, including Federal Law No. 152-FZ, are relevant.
6. Laboratory safety
Laboratories handling dangerous biological materials must maintain appropriate safety arrangements and comply with licensing and sanitary requirements applicable to their activities.
7. Emerging technologies
Synthetic biology, gene editing, gene drives, organoids and artificial biological systems raise questions that may not be fully addressed by existing technology-specific provisions.
11. Hypothetical legal illustrations
| Situation | Relevant legal framework | Possible legal consequence |
|---|---|---|
| Unregistered GMO cultivation | Law No. 86-FZ | Administrative enforcement |
| Biological laboratory accident | Law No. 492-FZ, Criminal Code Article 248 | Administrative or criminal liability |
| Unsafe experimental medicine | Laws Nos. 323-FZ and 61-FZ | Regulatory action and potential civil liability |
| Environmental contamination | Law No. 7-FZ, Civil Code Articles 1064 and 1065 | Compensation or preventive injunction |
| Unsafe clinical-trial procedures | Law No. 323-FZ | Civil, administrative or criminal consequences |
| Biological waste mismanagement | Laws Nos. 7-FZ and 89-FZ | Environmental enforcement |
These are illustrative applications; the actual legal consequences depend on the facts, applicable regulations and proof of the relevant statutory elements.
12. Conclusion
Biotechnology Risk Management Law in Russia is based on the principle that scientific innovation must operate within a system of public-health protection, environmental responsibility, regulatory supervision and legal accountability.
Federal Law No. 492-FZ of 2020 provides the general biological-safety framework, while Federal Law No. 86-FZ of 1996 governs genetic-engineering activities. Additional protection is provided through sanitary legislation, environmental laws, pharmaceutical regulations, civil liability and criminal law.
The cases discussed demonstrate three particularly important principles:
Protection of human life: Traskunova v. Russia demonstrates the importance of effective safeguards in clinical trials.
Regulatory compliance: The 2023 unregistered rapeseed proceedings illustrate the importance of GMO registration.
Environmental protection: Kotov and Others v. Russia and the environmental-liability framework demonstrate the importance of effective remedies against environmental hazards.
Ultimately, the Russian approach combines preventive regulation, scientific risk assessment, institutional supervision and liability for violations. Its continuing challenge is to ensure that rapidly developing biotechnology remains compatible with human safety, environmental protection and fundamental legal rights.
13. Important legal research references
For academic research, dissertations and examination preparation, the following primary and institutional sources are useful:
Federal Law No. 492-FZ – Biological Safety in Russia.
Federal Law No. 86-FZ – Genetic Engineering Activities.
Government Resolution No. 35 of 2023 – GMO Registration.
Federal Law No. 643-FZ – Amendments to Genetic Engineering Legislation.
Kotov and Others v. Russia (2022).
Library of Congress – Restrictions on GMOs in Russia.
FAO – Russian Federation GMO Safety Assessment.
Academic research note: The GMO case-law record is relatively limited. The 2014 Library of Congress report is useful historical comparative research, not a statement of the complete current position. For publication, verify the full text of the 2023 rapeseed judgment and the current consolidated Russian legislation.

comments